

MEETING ABSTRACTS

REACTIVATING EFFICACY OF OXIMES K203 AND K027 AGAINST A DIRECT ACETYLCHOLINESTERASE INHIBITOR IN RAT DIAPHRAGM: DOSE-RESPONSE MODELING

Evica Antonijevic¹, Kamil Musilek², Kamil Kuca³, Danijela Djukic-Cosic¹, Marijana Curcic¹, Zorica Bulat¹,
Biljana Antonijevic¹

¹ University of Belgrade, Faculty of Pharmacy, Department of Toxicology "Akademik Danilo Soldatović", Serbia

² University of Hradec Kralove, Faculty of Science, Department of Chemistry, Czech Republic

³ University Hospital in Hradec Kralove, Biomedical Research Center, Czech Republic

In efficacy testing of experimental oximes, traditionally reactivation of OP-inhibited acetylcholinesterase (AChE) has been analysed by comparing the obtained effects of the single dose with the control [1]. However, quantitative analysis of *in vivo* dose-response data by benchmark dose (BMD) approach would improve both identification and quantification of the effect and it will allow more rigorous comparison of different oximes efficacies [2]. Thus, we have evaluated *in vivo* dose-response relationship for two promising experimental oximes, K203 and K027, concerning reactivation of diaphragmal AChE inhibited by dichlorvos (DDVP). To compare the oximes effects, BMD-covariate method was used to estimate oxime dose (with 90% confidence intervals) that elicits a pre-specified effect size of 50% (1.5-fold increase in AChE activity compared to DDVP-treated group). Wistar rats (5/group) were treated with oxime (0/1.25/2.5/5/25/50% LD₅₀ *im*) immediately after DDVP challenge (75% LD₅₀ *sc*). Activity of AChE was measured in rat diaphragm homogenates by modified Ellman's method 60 min after the treatment. Dose-response modeling was done by PROAST software (version 65.5, RIVM, Netherlands). Exponential model m5-ab ($y=a[c-(c-1)\exp(-bx^d)]$) was selected as best estimate with parameters: $a_{K203}=0.1525$, $a_{K027}=0.1498$, $b_{K203}=0.008472$, $b_{K027}=0.03941$, $c=2.117$ and $d=0.8916$. Derived BMD₅₀ were K203=117 (56, 209) and K027=21 (10, 37) $\mu\text{mol/kg bw}$, indicating that oxime K027 induces the same effect size with 5.5-times lower dose compared to oxime K203. Moreover, obtained confidence intervals of BMDs did not overlap allowing the conclusion that more potent dose-response relationship belongs to experimental oxime K027.

Keywords: *dichlorvos; benchmark dose; oxime potency; rat diaphragm*

References

1. Antonijevic E, Musilek K, Kuca K, et al (2016) Therapeutic and reactivating efficacy of oximes K027 and K203 against a direct acetylcholinesterase inhibitor. *NeuroToxicology* 55:33–39.
2. Slob W (2017) A general theory of effect size, and its consequences for defining the benchmark response (BMR) for continuous endpoints. *Critical Reviews in Toxicology* 47:342–351.

Correspondence: evica.antonijevic@pharmacy.bg.ac.rs